SSA Swiss Advisors AG Lowers Stock Holdings in Sanofi $SNY

SSA Swiss Advisors AG trimmed its position in Sanofi (NASDAQ:SNY) by 12.7% during the second quarter, HoldingsChannel reports. The institutional investor owned 56,555 shares of the company’s stock after selling 8,205 shares during the period. SSA Swiss Advisors AG’s holdings in Sanofi were worth $2,808,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Accent Capital Management LLC purchased a new stake in shares of Sanofi in the first quarter worth about $29,000. Eastern Bank raised its stake in Sanofi by 121.0% in the first quarter. Eastern Bank now owns 548 shares of the company’s stock valued at $30,000 after purchasing an additional 300 shares in the last quarter. Ameritas Advisory Services LLC purchased a new stake in Sanofi in the second quarter valued at approximately $28,000. Golden State Wealth Management LLC raised its stake in Sanofi by 619.3% in the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company’s stock valued at $35,000 after purchasing an additional 545 shares in the last quarter. Finally, Banque Transatlantique SA purchased a new stake in Sanofi in the first quarter valued at approximately $33,000. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Up 4.3%

Shares of NASDAQ SNY opened at $51.64 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94. Sanofi has a one year low of $44.62 and a one year high of $60.12. The stock has a market capitalization of $126.80 billion, a P/E ratio of 12.41, a PEG ratio of 1.20 and a beta of 0.51. The firm’s 50 day simple moving average is $48.65 and its two-hundred day simple moving average is $49.55.

Sanofi (NASDAQ:SNY) last issued its earnings results on Friday, October 24th. The company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.10. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The firm had revenue of $14.53 billion for the quarter, compared to analysts’ expectations of $12.62 billion. During the same quarter last year, the business earned $2.25 earnings per share. The business’s revenue was down 7.5% on a year-over-year basis. As a group, analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $56.00 to $58.00 in a research note on Monday, September 8th. JPMorgan Chase & Co. raised shares of Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Barclays reiterated an “overweight” rating on shares of Sanofi in a research report on Wednesday, July 2nd. Finally, Wall Street Zen upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $62.67.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.